Philip J. Mease, MD

New advances in fibromyalgia are part of a larger shift in pain management in 2025.

Mease discussed the latest updates on apremilast and growing attention to cardiometabolic outcomes at ACR Convergence 2025.

Mease discussed the latest updates on deucravacitinib and zasocitinib at ACR Convergence 2025.

Mease discussed the latest updates on bimekizumab, sonelokimab, and izokibep at ACR Convergence 2025.

Mease discussed his hopes for the new approval's impact on the fibromyalgia field.

Recent phase 3 trials reveal promising results for Duravancinib in treating psoriatic arthritis, showcasing efficacy and a strong safety profile.

Mease described his real-world experience with using bimekizumab in the clinic for treating PsA and AxSpA.

Mease outlined positive efficacy and safety findings from multiple long-term follow-up trials of the biologic in people with PsA and AxSpA.

Mease discussed recent research on what matters in PsA care between patients and clinicians.

Mease discussed the expanding treatment landscape for PsA and how the field is integrating new biologics.

Philip J. Mease, MD, highlights the potential of blood biomarkers to assist with diagnosing fibromyalgia, as well as other imaging modalities.

Philip J. Mease, MD, discusses treatment selection in fibromyalgia, highlighting combination therapy as well as the importance of a holistic approach to care.

Philip J. Mease, MD, discusses treatment selection in fibromyalgia, highlighting combination therapy as well as the importance of a holistic approach to care.

An expert rheumatologist reviews the efficacy and safety of the 3 FDA-approved therapies for treating fibromyalgia—pregabalin, duloxetine, and milnacipran.

Philip J. Mease, MD, comments on the importance of education about fibromyalgia, especially regarding the stigma and the psychological impact of the disease.

Philip J. Mease, MD, provides an overview of fibromyalgia as a primary disorder of central pain processing and modulation.

In this MEDcast episode, Drs. Soloman, Sharobeem, and Mease discuss newer mechanisms of actions and emerging therapies in rheumatic diseases and tools that are becoming available to rheumatologists to practice precision medicine.

In this MEDcast episode, Drs. Soloman, Sharobeem, and Mease discuss newer mechanisms of actions and emerging therapies in rheumatic diseases and tools that are becoming available to rheumatologists to practice precision medicine.